MRK/Vorapaxar—Intracranial hemorrhage confirmed as the reason for terminating the TRACER study and restricting the patient pool in the TRA-2P study: http://finance.yahoo.com/news/Merck-Says-Additional-bw-2661003325.html?x=0&.v=1